Quality of life in patients with metastatic colorectal cancer receiving maintenance therapy after first-line inductive treatment: A quality of life sub-analysis of the AIO KRK 0207 phase III trial

被引：1
|
作者：
Quidde, J. t [1 ]
Becker, S. Hegewisch [2 ]
Graeven, U. [3 ]
Lerchenmueller, C.
Killing, B. [4 ]
Depenbusch, R.
Steffens, C. -C.
Lange, T. [5 ]
Dietrich, G. [6 ]
Stoehlmacher, J. [7 ]
Reinacher, A. [8 ]
Tannapfel, A. [9 ]
Trarbach, T. [10 ]
Marschner, N.
Schmoll, H. J. [11 ]
Hinke, A. [12 ]
Al-Batran, S. -E. [13 ]
Arnold, D. [14 ]
机构：
[1] Univ Hamburg Hosp, Univ Canc Ctr Hamburg, Hamburg, Germany
[2] HOPE, Internal Med Oncol & Hematol, Hamburg, Germany
[3] Kliniken Maria Hilf GmbH, Klin Haematolgie Onkol, Monchengladbach, Germany
[4] Lahn Dill Kliniken, Dept Hematol & Oncol, Wetzlar, Germany
[5] Asklepios Klin Weissenfels, Dept Hematol & Oncol, Weissenfels, Germany
[6] Klinikum Bietigheim, Dept Gastroenterol Hematol & Oncol, Bietigheim, Germany
[7] Tumorgenetik, Bonn, Germany
[8] Ruhr Univ Bochum, Med Univ Klin, Med Dept, Bochum, Germany
[9] Ruhr Univ Bochum, Med Univ Klin, Dept Pathol, Bochum, Germany
[10] IOMEDICO AG, Med Dept, Freiburg, Germany
[11] Martin Luther Univ Halle Wittenberg, Dept Hematol Oncol FG U1 16, Halle, Germany
[12] WiSP GmbH, Res, Langenfeld, Germany
[13] Nordwest Krankenhaus, Med Oncol, Frankfurt, Germany
[14] CUF Hosp Canc Ctr, CUF, Lisbon, Portugal
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw370.105
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
557P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Comparative analysis of different maintenance regimens after first-line induction in patients with metastatic colorectal cancer
    Mohamed, A. M. R.
    Abdallah, Nadine
    Ismail, Hibah
    Chen, Wei
    Jang, Hyejeong
    Smith, Daryn W.
    Akhras, Alaa
    Tesfaye, Anteneh A.
    Philip, Philip Agop
    Shields, Anthony Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [42] The relationship between quality of life, adverse events, and treatment efficacy in treatment with first-line chemotherapy plus cetuximab for unresectable metastatic colorectal cancer: Results of phase II QUACK trial
    Akira, O.
    Morita, S.
    Iwamoto, S.
    Hara, H.
    Tanioka, H.
    Satake, H.
    Kataoka, M.
    Tsuji, A.
    Ando, M.
    Sakamoto, J.
    Yamaguchi, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S90 - S90
  • [43] Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
    Thaler, Josef
    Karthaus, Meinolf
    Mineur, Laurent
    Greil, Richard
    Letocha, Henry
    Hofheinz, Ralf
    Fernebro, Eva
    Gamelin, Erick
    Banos, Ana
    Koehne, Claus-Henning
    BMC CANCER, 2012, 12
  • [44] Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
    Josef Thaler
    Meinolf Karthaus
    Laurent Mineur
    Richard Greil
    Henry Letocha
    Ralf Hofheinz
    Eva Fernebro
    Erick Gamelin
    Ana Baños
    Claus-Henning Köhne
    BMC Cancer, 12
  • [45] Quality of life (QoL) in patients with metastatic pancreatic cancer receiving first-line Nab-paclitaxel/gemcitabine chemotherapy: Results of the large QoL study AIO-QoliXane/PARAGON
    Schoenherr, C.
    Goetze, T. O.
    zur Hausen, G.
    Reichart, A.
    Pauligk, C.
    Schlag, R.
    Siegler, G. M.
    Doerfel, S.
    Aldaoud, A.
    Hahn, L.
    Schubert, J.
    Zahn, M-O.
    Hoeffkes, H-G.
    Reiser, M.
    Koenigsmann, M.
    Blau, W.
    Waidmann, O.
    Homann, N.
    Trojan, J.
    Al-Batran, S-E.
    ANNALS OF ONCOLOGY, 2018, 29 : 252 - 252
  • [46] Impact of first line FOLFOXIRI and Bevacizumab (Bev) compared to FOLFOX and Bev on health related quality of life (HRQOL) in patients with metastatic colorectal cancer (MCRCR) - analysis of the CHARTA - AIO 0209 trial
    Quidde, J.
    Nilsson, S.
    Schmoll, H. -J.
    Garlipp, B.
    Junghanss, C.
    Leithaeuser, M.
    Vogel, A.
    Schaefers, M.
    Kaiser, U.
    Hoeffkes, H. -G.
    Florschuetz, A.
    Ruessel, J.
    Kanzler, S.
    Edelmann, T.
    Forstbauer, H.
    Goehler, T.
    Hannig, C.
    Hildebrandt, B.
    Roll, C.
    Steighardt, J.
    Stein, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 208 - 208
  • [47] The relationship between quality of life (QoL) and tumor response in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab (pmab) plus FOLFIRI as first-line therapy: An analysis of study 314.
    Karthaus, M.
    Thaler, J.
    Hofheinz, R.
    Mineur, L.
    Letocha, H.
    Greil, R.
    Fernebro, E.
    Gamelin, E.
    Banos, A.
    Kohne, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [48] Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial
    Akira Ooki
    Satoshi Morita
    Akihito Tsuji
    Shigeyoshi Iwamoto
    Hiroki Hara
    Hiroaki Tanioka
    Hironaga Satake
    Masato Kataoka
    Masahito Kotaka
    Yoshinori Kagawa
    Masato Nakamura
    Tatsushi Shingai
    Masashi Ishikawa
    Yasuhiro Miyake
    Takeshi Suto
    Yojiro Hashiguchi
    Taichi Yabuno
    Masahiko Ando
    Junichi Sakamoto
    Kensei Yamaguchi
    BMC Cancer, 22
  • [49] Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial
    Ooki, Akira
    Morita, Satoshi
    Tsuji, Akihito
    Iwamoto, Shigeyoshi
    Hara, Hiroki
    Tanioka, Hiroaki
    Satake, Hironaga
    Kataoka, Masato
    Kotaka, Masahito
    Kagawa, Yoshinori
    Nakamura, Masato
    Shingai, Tatsushi
    Ishikawa, Masashi
    Miyake, Yasuhiro
    Suto, Takeshi
    Hashiguchi, Yojiro
    Yabuno, Taichi
    Ando, Masahiko
    Sakamoto, Junichi
    Yamaguchi, Kensei
    BMC CANCER, 2022, 22 (01)
  • [50] Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104-A Randomized Trial of the German AIO CRC Study Group
    Moosmann, Nicolas
    von Weikersthal, Ludwig Fischer
    Stauch, Martina
    Hass, Holger G.
    Dietzfelbinger, Herrmann
    Oruzio, Daniel
    Klein, Stefan
    Zellmann, Klaus
    Decker, Thomas
    Schulze, Mathias
    Abenhardt, Wolfgang
    Puchtler, Gerhard
    Kappauf, Herbert
    Mittermueller, Johann
    Haberl, Christopher
    Schalhorn, Andreas
    Jung, Andreas
    Stintzing, Sebastian
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (08) : 1050 - 1058
12345